Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 29, Issue 4, 2002, Pages 667-677

  Shergy, William J ^a   Isern, Reuben A ^a   Cooley, David A ^a   Harshbarger, John L ^a   Huffstutter, J Eugene ^a   Hughes, Gordon M ^a   Spencer Smith, Elizabeth A ^a   Goldman, Allan L ^a   Roth, Sanford H ^a   Toder, J Scott ^a   Warner, Diana ^a   Quinn, Adrienne ^a   Keenan, Gregory F ^a   Schaible, Thomas F ^a   Arkin, C ^a   Weiss, ^a   Berry, M ^a   Arthur, J ^a   Bong, D ^a   Burch, F ^a   Codding, C ^a   Cooley, D ^a   Eagan, M ^a   Forstot, J ^a   Goldman, A ^a   Greth, W ^a   Hague, J ^a   Halla, J ^a   Harshbarger, J ^a   Houk, L ^a   Huebner, C ^a   Jacobs, L ^a   Keller, M ^a   Kimelheim, R ^a   Kivitz, A ^a   Lawson, J ^a   Lidman, R ^a   Mandel, D ^a   Marcus, R ^a   Maestrello, S ^a   Melton III, J ^a   Miniter, M ^a   Mohr, B ^a   Oza, M ^a   Pick, M ^a   Porges, A ^a   Prupas, M ^a   Ridley, D ^a   Roth, S ^a   Katz, R ^a   Hughes, D F ^a   Saxe, P ^a   Schoen, R ^a   Shergy, W ^a   Sikes, D ^a   Smith Jr , J ^a   Trice, J ^a   Wallace, D ^a   Yahia, S ^a   Condemni, J ^a   D'Ambrosio, M ^a   Desir, D ^a   Huffstutter, J E ^a   Wheeler, P ^a   Ettlinger, R ^a   Silverman, H A ^a   Storch, M I ^a   Bayliss, G ^a   Lieberman, J ^a   Mease, P ^a   Soloway, S ^a   Wei, N ^a   Stainbrook Jr , D ^a   Vallance, D ^a   Malamet, R ^a   Rothenberg, R ^a   Gaylis, N ^a   Kunkel, G ^a   Carsons, S ^a   Gordon, R D ^a   Spencer Smith, E ^a   Kolba, K ^a   Toder, J S ^a   McLain, D ^a   Kaine, J ^a   Aelion, J ^a   Abeles, M ^a   Fraser, A ^a   Tesser, J ^a   Lawless, O ^a   St Clair, W ^a   more..

^a Rheumatology Associates of North Alabama   (United States)

Author keywords

DMARD; Infliximab; Methotrexate; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

AMBULATORY CARE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; OUTPATIENTS; PAIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036222685     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
2. 54-Week clinical and radiographic results from the ATTRACT trial: A phase I trial
3. 102-Wk clinical & radiologic results from the ATTRACT trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in patients with active RA despite MTX
4. New comparisons of two types of TNF-antagonists approved for rheumatoid arthritis
5. Anti-cytokine therapy for rheumatoid arthritis
6. Guidelines for the management of rheumatoid arthritis
7. The assessment and prediction of functional disability in rheumatoid arthritis
8. Biologic therapy for rheumatoid arthritis
9. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
10. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
11. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
12. Long term safety of infliximab
13. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
14. The future role of anti-tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis
15. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis